Search research articles
Contact Us
Filters
Showing results (91-100 of 105) with videos related to
Page
of 11
Sort By:
Journal of Hepatology
|
December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
Mary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Hepatology Communications
|
September 12, 2018
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Marlyn J Mayo, Alan J Wigg, Barbara A Leggett, et al.
Acta Dermato-Venereologica
|
November 19, 2025
Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study
Yajie Yu, Yanqing Chen, Yuping Zhang, et al.
American Journal of Respiratory Cell and Molecular Biology
|
May 13, 2022
FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice
Aurélien Justet, Mada Ghanem, Tiara Boghanim, et al.
Cancer Research
|
April 15, 2014
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou, Xueyan Wang, Van Phung, et al.
Frontiers in Chemistry
|
July 21, 2022
Abietane-Type Diterpenoids From <i>Nepeta bracteata</i> Benth. and Their Anti-Inflammatory Activity
Er-Lan Yang, Yong Hou, Guo-Xu Ma, et al.
Hepatology (Baltimore, Md.)
|
February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Lancet (London, England)
|
March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)
|
November 22, 2017
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice
Phillipp Hartmann, Katrin Hochrath, Angela Horvath, et al.
Scientific Reports
|
April 8, 2016
Loss-of-function Mutation in PMVK Causes Autosomal Dominant Disseminated Superficial Porokeratosis
Jiuxiang Wang, Ying Liu, Fei Liu, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 105) with videos related to
Sort By:
Page
of 11
Journal of Hepatology
|
December 12, 2018
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
Mary E Rinella, James F Trotter, Manal F Abdelmalek, et al.
Hepatology Communications
|
September 12, 2018
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Marlyn J Mayo, Alan J Wigg, Barbara A Leggett, et al.
Acta Dermato-Venereologica
|
November 19, 2025
Short-term Abrocitinib Combined with Medicated Topical Therapy Provides Rapid Improvement in Pruritus in Elderly Patients with Moderate-to-severe Atopic Dermatitis: A Retrospective, Observational Real-world Study
Yajie Yu, Yanqing Chen, Yuping Zhang, et al.
American Journal of Respiratory Cell and Molecular Biology
|
May 13, 2022
FGF19 Is Downregulated in Idiopathic Pulmonary Fibrosis and Inhibits Lung Fibrosis in Mice
Aurélien Justet, Mada Ghanem, Tiara Boghanim, et al.
Cancer Research
|
April 15, 2014
Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
Mei Zhou, Xueyan Wang, Van Phung, et al.
Frontiers in Chemistry
|
July 21, 2022
Abietane-Type Diterpenoids From <i>Nepeta bracteata</i> Benth. and Their Anti-Inflammatory Activity
Er-Lan Yang, Yong Hou, Guo-Xu Ma, et al.
Hepatology (Baltimore, Md.)
|
February 27, 2019
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A Harrison, Stephen J Rossi, Angelo H Paredes, et al.
Lancet (London, England)
|
March 10, 2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A Harrison, Mary E Rinella, Manal F Abdelmalek, et al.
Hepatology (Baltimore, Md.)
|
November 22, 2017
Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice
Phillipp Hartmann, Katrin Hochrath, Angela Horvath, et al.
Scientific Reports
|
April 8, 2016
Loss-of-function Mutation in PMVK Causes Autosomal Dominant Disseminated Superficial Porokeratosis
Jiuxiang Wang, Ying Liu, Fei Liu, et al.
Page
of 11